MCID: HYP071
MIFTS: 49

Hypersensitivity Reaction Type Ii Disease malady

Categories: Immune diseases, Cancer diseases

Aliases & Classifications for Hypersensitivity Reaction Type Ii Disease

Aliases & Descriptions for Hypersensitivity Reaction Type Ii Disease:

Name: Hypersensitivity Reaction Type Ii Disease 12 14
Autoimmune Diseases 52 41 69
Autoimmune Disorder 14
Autoimmune Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:417
ICD9CM 35 720
UMLS 69 C0003089

Summaries for Hypersensitivity Reaction Type Ii Disease

MedlinePlus : 41 your body's immune system protects you from disease and infection. but if you have an autoimmune disease, your immune system attacks healthy cells in your body by mistake. autoimmune diseases can affect many parts of the body. no one is sure what causes autoimmune diseases. they do tend to run in families. women - particularly african-american, hispanic-american, and native-american women - have a higher risk for some autoimmune diseases. there are more than 80 types of autoimmune diseases, and some have similar symptoms. this makes it hard for your health care provider to know if you really have one of these diseases, and if so, which one. getting a diagnosis can be frustrating and stressful. often, the first symptoms are fatigue, muscle aches and a low fever. the classic sign of an autoimmune disease is inflammation, which can cause redness, heat, pain and swelling. the diseases may also have flare-ups, when they get worse, and remissions, when symptoms get better or disappear. treatment depends on the disease, but in most cases one important goal is to reduce inflammation. sometimes doctors prescribe corticosteroids or other drugs that reduce your immune response.

MalaCards based summary : Hypersensitivity Reaction Type Ii Disease, also known as autoimmune diseases, is related to celiac disease and autoimmune disease of skin and connective tissue, and has symptoms including autoimmune antibody positivity An important gene associated with Hypersensitivity Reaction Type Ii Disease is TLR9 (Toll Like Receptor 9), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Simvastatin and Azithromycin have been mentioned in the context of this disorder. Affiliated tissues include t cells, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 An immune system disease that is an overactive immune response of the body against substances and tissues normally present in the body resulting from an abnormal functioning of the immune system that results in the production of antibodies or T cell directed against the host tissues.

Related Diseases for Hypersensitivity Reaction Type Ii Disease

Diseases in the Hypersensitivity Reaction Type Ii Disease family:

Hypersensitivity Reaction Type Iii Disease Hypersensitivity Reaction Type Iv Disease

Diseases related to Hypersensitivity Reaction Type Ii Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 294)
id Related Disease Score Top Affiliating Genes
1 celiac disease 32.2 CD40LG CD79A IL17A TNF
2 autoimmune disease of skin and connective tissue 32.1 CD40LG CD79A CTLA4 IFNG
3 stiff-person syndrome 31.8 APOH CD40LG IFNG PTPN22
4 goodpasture syndrome 31.8 APOH CD40LG CD79A CTLA4 IFNG IL10
5 rheumatoid arthritis 31.2 CD40LG CD79A CTLA4 FOXP3 IFNG IL10
6 pandas 11.2
7 familial mediterranean fever, ar 11.0
8 vitiligo-associated multiple autoimmune disease susceptibility 1 11.0
9 autoimmune disease of endocrine system 11.0
10 autoimmune disease of eyes, ear, nose and throat 11.0
11 autoimmune disease of gastrointestinal tract 11.0
12 autoimmune disease of urogenital tract 11.0
13 autoimmune disease of blood 11.0
14 autoimmune disease of cardiovascular system 11.0
15 vogt-koyanagi-harada disease 11.0
16 sjogren's syndrome 11.0
17 rheumatic disease 11.0
18 antiphospholipid syndrome 11.0
19 alopecia areata 11.0
20 neuromyelitis optica 10.9
21 systemic lupus erythematosus 10.8
22 complement component 8 deficiency 10.5 AIRE CTLA4 PTPN22
23 pyridoxal 5'-phosphate-dependent epilepsy 10.4 IL10 TNF
24 dermatitis herpetiformis 10.4 CD40LG IL17A TNF
25 aniseikonia 10.4 IFNG IL17A TNF
26 tubular renal disease-cardiomyopathy syndrome 10.4 IL10 IL4 TNF
27 alcoholic neuropathy 10.4 CD40LG CD79A
28 camptodactyly vertebral fusion 10.4 CD40LG CD79A
29 polyarteritis nodosa 10.4 IFNG IL17A TLR9
30 pedophilia 10.4 CD40LG CD79A TLR9
31 lagophthalmos 10.4 IL10 IL4 TNF
32 reproductive system disease 10.4 CD40LG IL10 IL17A
33 conidiobolomycosis 10.4 IL10 IL4 TNF
34 primary lacrimal atrophy 10.4 CD40LG CD79A CTLA4
35 conjunctival deposit 10.4 CTLA4 TG TPO
36 myoglobinuria recurrent 10.4 IFNG IL4
37 toxocariasis 10.4 CD79A TRIM21
38 atheroembolism of kidney 10.4 CD40LG CD79A TG
39 vestibule of mouth cancer 10.4 IL10 IL4 TNF
40 fibrous meningioma 10.4 IL2 TG TPO
41 pneumoconiosis 10.4 TNF TNFSF13B TRIM21
42 amyotrophic lateral sclerosis type 14 10.4 IFNG IL2 TNF
43 asymptomatic neurosyphilis 10.4 IFNG IL10 IL4
44 parametritis 10.4 IFNG IL2 TNF
45 steatitis 10.4 IL2 TNF
46 color blindness 10.4 AIRE TG TPO
47 senile reticular retinal degeneration 10.4 IFNG IL10 TNF
48 uveitis 10.4 CD40LG CD79A TNF
49 hypoparathyroidism-retardation-dysmorphism syndrome 10.4 IL10 TNF TRIM21
50 acute gonococcal prostatitis 10.4 CTLA4 IFNG IL4

Graphical network of the top 20 diseases related to Hypersensitivity Reaction Type Ii Disease:



Diseases related to Hypersensitivity Reaction Type Ii Disease

Symptoms & Phenotypes for Hypersensitivity Reaction Type Ii Disease

Human phenotypes related to Hypersensitivity Reaction Type Ii Disease:

32
id Description HPO Frequency HPO Source Accession
1 autoimmune antibody positivity 32 HP:0030057

MGI Mouse Phenotypes related to Hypersensitivity Reaction Type Ii Disease:

44 (show all 15)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.47 IL4 MBP PADI4 PTPN22 TG TLR9
2 homeostasis/metabolism MP:0005376 10.43 APOH CD40LG CD79A CTLA4 FOXP3 IFNG
3 immune system MP:0005387 10.41 AIRE CD40LG CD79A CTLA4 FOXP3 IFNG
4 endocrine/exocrine gland MP:0005379 10.34 AIRE CD40LG CTLA4 FOXP3 IFNG IL10
5 cellular MP:0005384 10.33 IFNG IL10 IL2 IL4 MBP PTPN22
6 mortality/aging MP:0010768 10.33 TNF TPO TRIM21 AIRE APOH CD40LG
7 growth/size/body region MP:0005378 10.32 AIRE FOXP3 IFNG IL10 IL17A IL2
8 digestive/alimentary MP:0005381 10.28 AIRE CTLA4 FOXP3 IFNG IL10 IL17A
9 liver/biliary system MP:0005370 10.13 AIRE CD79A CTLA4 FOXP3 IFNG IL10
10 no phenotypic analysis MP:0003012 10.02 IL2 IL4 TNF AIRE CD79A FOXP3
11 normal MP:0002873 9.97 AIRE CD79A CTLA4 FOXP3 IFNG IL10
12 renal/urinary system MP:0005367 9.91 CD40LG CD79A FOXP3 IFNG IL17A IL4
13 reproductive system MP:0005389 9.81 AIRE CD40LG FOXP3 IFNG IL10 IL2
14 respiratory system MP:0005388 9.65 IL10 IL17A AIRE CTLA4 FOXP3 IFNG
15 vision/eye MP:0005391 9.28 AIRE FOXP3 IFNG IL10 IL2 IL4

Drugs & Therapeutics for Hypersensitivity Reaction Type Ii Disease

Drugs for Hypersensitivity Reaction Type Ii Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1286)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
2
Azithromycin Approved Phase 4,Phase 2,Phase 1 83905-01-5 55185 53477736 447043
3
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
4
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
6
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
7
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 128794-94-5 5281078
8
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 24280-93-1 446541
9
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
10
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
11
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 104987-11-3 445643 439492
12
Selenium Approved, Vet_approved Phase 4,Phase 2,Phase 1 7782-49-2
13
Pancrelipase Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 53608-75-6
14
Azathioprine Approved Phase 4,Phase 3,Phase 2,Phase 1 446-86-6 2265
15
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7440-66-6 32051 23994
16
Febuxostat Approved Phase 4,Phase 2 144060-53-7 134018
17
Nitric Oxide Approved Phase 4,Phase 2,Phase 1 10102-43-9 145068
18
Nitroglycerin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 55-63-0 4510
19
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
20
Insulin Aspart Approved Phase 4,Phase 3,Phase 2,Phase 1 116094-23-6 16132418
21
Insulin Lispro Approved Phase 4,Phase 3,Phase 2,Phase 1 133107-64-9
22
Insulin-glulisine Approved Phase 4,Phase 3,Phase 2,Phase 1 207748-29-6
23
Liraglutide Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 204656-20-2
24
Insulin Detemir Approved Phase 4,Phase 3,Phase 2,Phase 1 169148-63-4 5311023
25
Insulin Glargine Approved Phase 4,Phase 3,Phase 2,Phase 1 160337-95-1
26
Glyburide Approved Phase 4,Phase 2,Phase 3 10238-21-8 3488
27
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-23-7 5754 657311
28
Natalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 189261-10-7
29
Mitoxantrone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 65271-80-9 4212
30
Glatiramer Acetate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147245-92-9 3081884
31
Interferon beta-1b Approved Phase 4,Phase 3,Phase 2,Phase 1 145155-23-3
32
4-Aminopyridine Approved Phase 4,Phase 3,Phase 2 504-24-5 1727
33
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 185243-69-0
34
Leflunomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 75706-12-6 3899
35
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
36
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 2,Phase 1 118-42-3 3652
37
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1 170277-31-3
38
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3 16590-41-3 5360515
39
Sulfasalazine Approved Phase 4,Phase 3,Phase 2 599-79-1 5353980 5359476
40
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1 331731-18-1 16219006
41
Atenolol Approved Phase 4,Phase 2 29122-68-7 2249
42
Ramipril Approved Phase 4,Phase 3,Phase 2,Early Phase 1 87333-19-5 5362129
43
Ticlopidine Approved Phase 4,Phase 1,Phase 2 55142-85-3 5472
44
Amlodipine Approved Phase 4,Phase 3 88150-42-9 2162
45
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 58-93-5 3639
46
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 137862-53-4 60846
47
Linagliptin Approved Phase 4,Phase 2 668270-12-0 10096344
48
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1 657-24-9 14219 4091
49
Voglibose Approved, Investigational Phase 4 83480-29-9 444020
50
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 64-17-5 702

Interventional clinical trials:

(show top 50) (show all 6506)
id Name Status NCT ID Phase
1 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Unknown status NCT00815282 Phase 4
2 Calcitriol in the Treatment of Immunoglobulin A Nephropathy Unknown status NCT00862693 Phase 4
3 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level Unknown status NCT00866229 Phase 4
4 Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease Unknown status NCT00188188 Phase 4
5 Hanyang University Medical Center Arthritis Network Unknown status NCT00418405 Phase 4
6 An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum Unknown status NCT02199925 Phase 4
7 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
8 The Efficacy of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease Unknown status NCT01469702 Phase 4
9 Study of Qiliqiangxin Capsule to Treat Dilated Cardiomyopathy Unknown status NCT01293903 Phase 4
10 Intralipid Therapy for Recurrent Implantation Failure and Recurrent Miscarriages: Is it a Hope or Myth?A Randomized Clinical Trial Unknown status NCT01679561 Phase 4
11 Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant Unknown status NCT02084446 Phase 4
12 Selenium Supplementation in Pregnancy Unknown status NCT01465867 Phase 4
13 Mixed Meal Test in Type 1 Diabetes: Optimization of Artificial Pancreas-Pilot Study Unknown status NCT01800734 Phase 4
14 Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis Unknown status NCT00128895 Phase 4
15 Mixed Meal Test in Type 1 Diabetes on Insulin Pump Therapy: Optimization of Artificial Pancreas Unknown status NCT02003274 Phase 4
16 The Effect of Uric Acid Lowering in Type 1 Diabetes Unknown status NCT02344602 Phase 4
17 A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy Unknown status NCT01184599 Phase 4
18 Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes Unknown status NCT01280682 Phase 4
19 Treatment of Low Blood Sugar With Glucagon Among Patients With Type 1 Diabetes Unknown status NCT02232971 Phase 4
20 CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM) Unknown status NCT01848990 Phase 4
21 52 Week Trial of Liraglutide in Type 1 Diabetes Unknown status NCT01787916 Phase 4
22 Comparing Long-acting Insulins During Exercise in Type 1 Diabetes Unknown status NCT01440439 Phase 4
23 Psychosocial Issues in Insulin Pump Therapy in Children With Type 1 DM Unknown status NCT01338922 Phase 4
24 Timing of Initiation of Continuous Glucose Monitoring in Established Pediatric Diabetes (The CGM TIME Trial) Unknown status NCT01295788 Phase 4
25 Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis Unknown status NCT01271517 Phase 4
26 Real-Time Continuous Glucose Monitoring in Pre-School Children With Type-1 Diabetes Mellitus Unknown status NCT01016457 Phase 4
27 Do Sulphonylureas Preserve Cortical Function During Hypoglycaemia? Unknown status NCT00472875 Phase 4
28 Insulin NovoRapid Versus Actrapid in Treatment of Type 1 Diabetic Patients During Daily Adjustment of Insulin Dose Unknown status NCT00145353 Phase 4
29 Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya Unknown status NCT02325440 Phase 4
30 Impact of Vitamin A on Multiple Sclerosis (MS) Unknown status NCT01417273 Phase 4
31 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4
32 Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) Unknown status NCT00910598 Phase 4
33 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
34 Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI Unknown status NCT00176592 Phase 4
35 A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis Unknown status NCT01838174 Phase 4
36 Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS Unknown status NCT02259361 Phase 4
37 Resistance Training and Amino Pyridine in Multiple Sclerosis Unknown status NCT02143167 Phase 4
38 Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis Unknown status NCT01705457 Phase 4
39 Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient Unknown status NCT01407211 Phase 4
40 Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS) Unknown status NCT01339676 Phase 4
41 Multimodal MRI in Multiple Sclerosis (MS): Reliability and Follow Up Unknown status NCT00289159 Phase 4
42 Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis Unknown status NCT01400464 Phase 4
43 Targeting Synovitis in Early Rheumatoid Arthritis Unknown status NCT00920478 Phase 4
44 Efficacy Study of Leflunomide to Treat Juvenile Idiopathic Arthritis Unknown status NCT02024334 Phase 4
45 Evaluation Effects of Treatment With IL-6R Inhibitor on Clinical Response and Biomarkers in Patients With Rheumatoid Arthritis (RA) Not Responding to DMARDs and/or a First Biological Agent. Unknown status NCT01835613 Phase 4
46 TNF-blocking Therapy in Combination With Disease-modifying Antirheumatic Drugs in Early Rheumatoid Arthritis Unknown status NCT00908089 Phase 4
47 Bucillamine Study of Holding Remission After Infliximab Dose-off Unknown status NCT00716248 Phase 4
48 Multicenter Randomized Prospective Trial Comparing Methotrexate Alone or in Combination With Adalimumab in Early Arthritis Unknown status NCT00291915 Phase 4
49 Study of Iguratimod Plus Methotrexate Compared to Leflunomid Plus Methotrexate in Patients With Rheumatoid Arthritis Unknown status NCT02275299 Phase 4
50 Withdrawal of Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis Unknown status NCT01287715 Phase 4

Search NIH Clinical Center for Hypersensitivity Reaction Type Ii Disease

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Hypersensitivity Reaction Type Ii Disease

Anatomical Context for Hypersensitivity Reaction Type Ii Disease

MalaCards organs/tissues related to Hypersensitivity Reaction Type Ii Disease:

39
T Cells

Publications for Hypersensitivity Reaction Type Ii Disease

Variations for Hypersensitivity Reaction Type Ii Disease

Copy number variations for Hypersensitivity Reaction Type Ii Disease from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 21625 1 159859611 159867782 Copy number FCGR3B Autoimmune disease
2 21792 1 161592989 161601158 Copy number FCGR3B Autoimmune disease
3 21796 1 161592989 161601158 Deletion FCGR3B Autoimmune disease
4 208909 6 211050653 211252076 Copy number CYP21B Autoimmune disease
5 210508 6 30400000 36600000 Copy number CYP21A Autoimmune disease
6 210509 6 30400000 36600000 Copy number TNXA Autoimmune disease
7 211044 6 3197570 32111174 Copy number C4A Autoimmune disease
8 211046 6 3197570 32111174 Copy number C4B Autoimmune disease

Expression for Hypersensitivity Reaction Type Ii Disease

Search GEO for disease gene expression data for Hypersensitivity Reaction Type Ii Disease.

Pathways for Hypersensitivity Reaction Type Ii Disease

Pathways related to Hypersensitivity Reaction Type Ii Disease according to GeneCards Suite gene sharing:

(show all 50)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 CD40LG CD79A CTLA4 IFNG IL10 IL17A
2
Show member pathways
13.42 CD40LG IL10 IL17A IL2 IL4 TLR9
3
Show member pathways
13.39 CD40LG IFNG IL10 IL17A IL2 IL4
4
Show member pathways
13.31 CD40LG IL10 IL17A IL2 IL4 PTPN22
5
Show member pathways
12.8 IFNG IL2 IL4 TLR9 TNF
6
Show member pathways
12.71 CD40LG IL2 TLR9 TNF TNFSF13B
7
Show member pathways
12.71 CD40LG CD79A IFNG IL10 IL2 IL4
8
Show member pathways
12.67 CD40LG CTLA4 FOXP3 IFNG IL10 IL17A
9
Show member pathways
12.66 FOXP3 IFNG IL10 IL17A IL2 IL4
10
Show member pathways
12.59 IFNG IL10 IL17A IL2 TNF
11
Show member pathways
12.34 CD40LG CTLA4 IFNG IL10 IL17A IL2
12
Show member pathways
12.33 IFNG IL2 IL4 TNF
13
Show member pathways
12.33 IFNG IL17A IL4 TNF
14
Show member pathways
12.29 CD40LG IFNG IL10 IL4 TNF
15 12.24 IFNG IL10 TLR9 TNF
16
Show member pathways
12.23 IFNG IL10 IL17A IL2 IL4 TNF
17
Show member pathways
12.22 IFNG IL10 IL2 IL4
18
Show member pathways
12.18 IFNG IL4 TLR9 TNF
19 12.09 IFNG IL2 IL4 MBP TNF TNFSF13B
20 12.06 CD79A IFNG IL10 IL2 IL4 TNF
21 12 IL10 IL17A IL4 TNF
22
Show member pathways
11.98 IFNG IL10 IL17A IL2 TLR9 TNF
23
Show member pathways
11.94 IFNG IL17A IL4 TLR9
24 11.94 CTLA4 IFNG IL17A TNF TNFSF13B
25 11.93 CD40LG CD79A CTLA4 FOXP3 IFNG IL10
26 11.84 IFNG IL10 IL2 TLR9 TNF
27 11.79 IFNG IL2 IL4
28 11.78 IFNG IL10 IL17A IL2 IL4 TNF
29
Show member pathways
11.74 CD40LG TNF TNFSF13B
30
Show member pathways
11.72 CD40LG IFNG IL2 TNF
31
Show member pathways
11.7 FOXP3 IL2 IL4
32 11.7 IFNG IL10 IL2
33
Show member pathways
11.68 CD40LG CTLA4 FOXP3 IFNG IL2 IL4
34 11.66 CD40LG IL10 IL4
35
Show member pathways
11.65 IFNG IL2 TNF
36 11.61 CD40LG IFNG IL10 TLR9 TNF
37 11.56 IFNG IL2 TNF
38 11.56 FOXP3 IFNG IL10 IL2 IL4
39 11.53 IL10 IL4 TNF
40 11.52 IFNG IL2 TNF
41
Show member pathways
11.46 FOXP3 IFNG IL10 IL2 TNF
42 11.45 IFNG IL10 TLR9 TNF
43 11.42 CD40LG IFNG IL2 IL4
44 11.4 IFNG IL17A IL4 TNF
45 11.4 CD40LG CTLA4 FOXP3 IL10 IL4 TLR9
46 11.39 AIRE CD40LG CD79A
47 11.28 IFNG IL10 IL2 IL4
48